Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 5 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Susceptibility-guided and empiric therapy equally effective in H. pylori infection

22 May 2019

Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.

Researchers conducted a multicentre superiority‐design trial, which randomly assigned 382 patients with H. pylori infection to (a) susceptibility‐guided therapies containing esomeprazole 20 mg and amoxicillin 1 g twice daily plus clarithromycin 500 mg, metronidazole 400 mg twice daily, or levofloxacin 500 mg daily for susceptible infections or bismuth 220 mg twice daily and metronidazole 400 mg four times daily for triple‐resistant infections; or to (b) empiric therapy containing esomeprazole 20 mg, bismuth 220 mg twice daily, amoxicillin 1 g and metronidazole 400 mg thrice daily.

Rates of H. pylori eradication were high and similar in the susceptibility‐guided and the empiric regimens (per-protocol rates: 97.7 percent vs 97.6 percent; p=1.00; intent‐to‐treat rates: 91.6 percent vs 85.4 percent; p=0.12).

Overall, susceptibility‐guided therapy was not superior to empiric therapy, with a difference of 0.1 percent in per‐protocol rate and 6.2 percent in intent‐to‐treat rate. Furthermore, both treatment approaches had high adherence and were associated with low adverse event rates.

In light of the findings, researchers pointed out that choosing between the two approaches would depend on availability of susceptibility testing and/or a locally highly effective empiric therapy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 5 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.